赵海涛，1972年生，籍贯天津市，北京协和医院肝脏外科主任医师，博士生导师。1989年考入北京医科大学临床医学专业，1994年获得学士学位。2001年在北京大学医学部外科学专业攻读硕士学位，从事临床医学研究。2010年在永利集团3044官网欢迎您外科学专业攻读博士学位，从事外科学研究。2010年升为副主任医师。2017年升为主任医师。

研究方向专注于肝癌的基础研究与临床应用研究，主要研究兴趣在于通过高通量测序研究肝胆系统恶性肿瘤发病机制、基因分型，鉴定肿瘤治疗靶点，应用于临床的精准医疗转化研究。团队长期致力于肝胆恶性肿瘤的靶向免疫治疗、基因组学、肿瘤异质性及起源重大临床科研问题。

1. Lin J#, Peng X#, Dong K#, Long J#, Guo X, Li H, Bai Y, Yang X, Wang D, Lu X, Mao Y, Sang X, Ji X, Zhao H*, Liang H*.Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nature Communications. 2021 Aug 6;12(1):4753. (IF=14.919)

2. Long J#, Huang S#, Bai Y#, Mao J#, Wang A, Lin Y, Yang X, Wang D, Lin J, Bian J, Yang X, Sang X*, Wang X*, Zhao H*. Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis., Brief Bioinform, 2021, 20(22): 224. (IF=11.622)

3. Yang X#, Hu Y#, Yang K#, Wang D#, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X*, Zhang H*, Zhao H*. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021 May;9(5):e001942. (IF=13.751)

4. Lin J#, Cao Y#, Yang X#, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H*, Wang K*, Wang X*, Zhao H*.Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021 Mar 4;11(10):4585-4598 . (IF=11.556)

5. Lin J#, Shi J#, Guo H#, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K*, Zhao H*.Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clin Cancer Res. 2019 Aug 1;25(15):4701-4711. (IF=10.107)

6. Long J#, Wang A#, Bai Y#, Lin J, Yang X, Wang D, Yang X, Jiang Y, Zhao H*. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019 Apr;42:363-374. (IF=8.143, ESI)

7. Wang A#, Wu L#, Lin J#, Han L, Bian J, Wu Y, Robson SC, Xue L, Ge Y, Sang X*, Wang W*, Zhao H*.Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nature Communications. 2018 Mar 1;9(1):894. (IF=11.878)

8. Long J#, Lin J#, Wang A#, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017 Aug 3;10(1):146. (IF=7.333)

9. Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H*, Teschendorff AE*. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res. 2017 Jan 4;45(D1):D812-D818.  (IF=11.162)

10. Long J#, Lin J#, Wang A#, Wu L, Zheng Y, Yang X, Wan X, Xu H*, Chen S*, Zhao H*.Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. Journal of Hepatology 2014 Oct;61(4):840-849. (IF=11.336)